Research
Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials
BMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39136.682083.AE (Published 12 April 2007) Cite this as: BMJ 2007;334:786Related articles
- Editorial Published: 12 April 2007; BMJ 334 doi:10.1136/bmj.39176.461227.80
- Education And Debate Published: 10 March 2005; BMJ 330 doi:10.1136/bmj.330.7491.594
- Research Published: 01 November 2010; BMJ 341 doi:10.1136/bmj.c5707
- Research Methods & Reporting Published: 09 January 2013; BMJ 346 doi:10.1136/bmj.e7586
- Research Published: 29 January 2013; BMJ 346 doi:10.1136/bmj.f457
- Research Methods & Reporting Published: 22 November 2013; BMJ 347 doi:10.1136/bmj.f6782
- Views & Reviews Published: 20 August 2014; BMJ 349 doi:10.1136/bmj.g5239
- Education And Debate Published: 04 September 2003; BMJ 327 doi:10.1136/bmj.327.7414.557
- Research Published: 18 August 2010; BMJ 341 doi:10.1136/bmj.c3920
- Analysis Published: 07 February 2019; BMJ 364 doi:10.1136/bmj.l341
- Practice Published: 30 July 2020; BMJ 370 doi:10.1136/bmj.m2924
- Research Published: 29 March 2023; BMJ 380 doi:10.1136/bmj-2022-072003
See more
- Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysisBMJ December 05, 2016, 355 i6188; DOI: https://doi.org/10.1136/bmj.i6188
- NHS to fund large trial of pre-exposure prophylaxis for HIV preventionBMJ December 05, 2016, 355 i6537; DOI: https://doi.org/10.1136/bmj.i6537
- Bill to boost medical research funding and speed drug approval passes US houseBMJ December 01, 2016, 355 i6498; DOI: https://doi.org/10.1136/bmj.i6498
- Alpha blockers for treatment of ureteric stones: systematic review and meta-analysisBMJ December 01, 2016, 355 i6112; DOI: https://doi.org/10.1136/bmj.i6112
- Sixty seconds on . . . solanezumabBMJ November 29, 2016, 355 i6389; DOI: https://doi.org/10.1136/bmj.i6389
Cited by...
- Comparison of seven popular structured dietary programmes and risk of mortality and major cardiovascular events in patients at increased cardiovascular risk: systematic review and network meta-analysis
- Estimating and Testing an Index of Bias Attributable to Composite Outcomes in Comparative Studies
- Remdesivir for severe covid-19: a clinical practice guideline
- Use of the Win Ratio in Cardiovascular Trials
- Identifying adverse events: reflections on an imperfect gold standard after 20 years of patient safety research
- Composite Outcome Improves Feasibility of Clinical Trials in Peritoneal Dialysis
- Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews
- PREDIMED trial of Mediterranean diet: retracted, republished, still trusted?
- Response to Comment on Itoh et al. Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care 2018;41:1275-1284
- Cardiovascular Outcomes Reported in Hemodialysis Trials
- Prognostic Impact of Subsequent Acute Coronary Syndrome and Unplanned Revascularization on Long-Term Mortality After an Index Percutaneous Coronary Intervention: A Report From a Japanese Multicenter Registry
- Temporal Trends in Use of Composite End Points in Major Cardiovascular Randomized Clinical Trials in Prominent Medical Journals
- Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?
- Composite End Points: Implications of Changing Compositions With Longer Follow-Up
- Cholesterol paradox: a correlate does not a surrogate make
- Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure: A 20-Year Perspective
- Big Science: Research Collaboration for Evidence-Based Care
- Health Status Outcomes in Patients With Acute Myocardial Infarction After Rehospitalization
- Selection of the primary end point in an observational cohort study
- Clinical Relevance of Rehospitalizations for Unstable Angina and Unplanned Revascularization Following Acute Myocardial Infarction
- Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful?
- Evaluating Statin Versus Statin Plus Ezetimibe for Coronary Plaque Regression
- The statin diabetes conundrum: short-term gain, long-term risk or inconvenient truth?
- Rethinking Composite End Points in Clinical Trials: Insights From Patients and Trialists
- Electronic health records may threaten blinding in trials of statins
- Informed Choice of Composite End Points in Cardiovascular Trials
- Dangers of non-specific composite outcome measures in clinical trials
- Should people at low risk of cardiovascular disease take a statin?
- SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
- Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study
- Comparison of the Prognosis of Spontaneous and Percutaneous Coronary Intervention-Related Myocardial Infarction
- Use and Interpretation of Composite End Points in Orthopaedic Trials
- The idolatry of the surrogate
- Weighting Components of Composite End Points in Clinical Trials: An Approach Using Disability-Adjusted Life-Years
- Outcome selection and role of patient reported outcomes in contemporary cardiovascular trials: systematic review
- Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review
- Bivalirudin in Acute Myocardial Infarction: "Primum Non Nocere": The Eternal Dilemma: Balancing Risks and Benefits in High-Risk Patients
- ACCF/AHA 2010 Position Statement on Composite Measures for Healthcare Performance Assessment: American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop a Position Statement on Composite Measures)
- ACCF/AHA 2010 Position Statement on Composite Measures for Healthcare Performance Assessment: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop a Position Statement on Composite Measures)
- Trial and Error: How to Avoid Commonly Encountered Limitations of Published Clinical Trials
- Aspirin for the Primary Prevention of Cardiovascular Events: A systematic review and meta-analysis comparing patients with and without diabetes
- Reply
- End Points for Clinical Trials in Acute Heart Failure Syndromes
- Randomized Trial of Reamed and Unreamed Intramedullary Nailing of Tibial Shaft Fractures
- Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments: A Network Meta-Analysis Involving More Than 65,000 Patients
- Performance indicators in acute myocardial infarction: a proposal for the future assessment of good quality care
- Use of Ordinal Outcomes in Vascular Prevention Trials: Comparison With Binary Outcomes in Published Trials * Supplemental Appendix I: Statistical Tests Compared * Supplemental Appendix II: Supplementary Analyses * Supplemental Appendix III: Results
- Beyond the Randomized Clinical Trial: The Role of Effectiveness Studies in Evaluating Cardiovascular Therapies
- The concept of prevention: a good idea gone astray?
- Periprocedural Bleeding and 1-Year Outcome After Percutaneous Coronary Interventions: Appropriateness of Including Bleeding as a Component of a Quadruple End Point
- The Problem With Composite End Points in Cardiovascular Studies: The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention
- COPD dashboard: about official Documents, Authors, Science, Health status and BOARDs
- Waking up from the DREAM of preventing diabetes with drugs
- Composite and surrogate outcomes in randomised controlled trials